Waissengrin Barliz, Wolf Ido
Oncology Institute, Tel Aviv Medical Center, Israel.
Sackler Faculty of Medicine, Tel Aviv, Israel.
Harefuah. 2020 Dec;159(12):867-869.
The SARS-COV-2 virus emerged in Israel in March 2020 and compelled restructuring of the Israeli health care system. Despite the paucity of data, it appears that oncology patients suffer from a higher risk of complications due to COVID-19 infection, including hospitalization in the intensive care unit (ICU) and death. A delicate balance exists between the oncologists' obligation to provide optimal and effective cancer treatment and the risks enveloping treatment that may place patients vulnerable to contraction of the virus. In an effort to reorganized oncological units, guidelines were published by the American and European oncology unions (ASCO, ESMO), including cancellation of frontal meetings, converting to telemedicine and changes in treatment protocols mitigating the exposure of patients to hospital visitations. Khoury et al. reported their experiences and challenges at Bnai Zion Hospital in Haifa during the first days of the pandemic, recounting the protection of staff, patients and reorganization of the oncological unit.
2020年3月，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒在以色列出现，促使以色列医疗保健系统进行重组。尽管数据匮乏，但肿瘤患者似乎因感染新冠病毒而出现并发症的风险更高，包括入住重症监护病房（ICU）和死亡。肿瘤学家提供最佳有效癌症治疗的义务与治疗带来的风险（可能使患者易感染病毒）之间存在微妙的平衡。为重组肿瘤科室，美国和欧洲肿瘤学联盟（美国临床肿瘤学会、欧洲肿瘤内科学会）发布了指南，包括取消面对面会议、改用远程医疗以及改变治疗方案以减少患者前往医院就诊的暴露风险。胡里等人报告了他们在海法的贝奈锡安医院在疫情最初几天的经历和挑战，讲述了对工作人员、患者的保护以及肿瘤科室的重组情况。
